An observational study in CABG, Visceral Adipose Tissue and Atrial Fibrillation (AF), sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Obesity has become a major public health problem in both developed and developing countries, with a continuous increase particularly since the 1980s. Moreover, it is a well-established metabolic risk factor for diabetes mellitus, hypertension, and various types of cancer, as well as cardiovascular diseases such as heart failure and coronary artery disease. Body mass index (BMI) is calculated by dividing body weight in kilograms by the square of height in meters and is widely used as an indicator of obesity. However, BMI does not quantitatively reflect body fat distribution and fails to account for components such as skeletal muscle and bone mass. Therefore, interest in assessing body fat distribution has increased, and in recent years, studies evaluating the correlation between anthropometric, biochemical, and anatomical measurements and clinical outcomes have become more frequent. In particular, it is acknowledged that abdominal obesity cannot be accurately represented by BMI alone and is primarily associated with visceral adipose tissue (VAT). The aim of this study is to evaluate the association between preoperative visceral and subcutaneous adipose tissue measurements (VAT and SAT), assessed by ultrasonography in patients scheduled for open-heart surgery, and the development of postoperative atrial fibrillation.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
This study's planned enrollment of 300 is close to the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital is the lead sponsor of 22 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients (≥18 years) scheduled for coronary artery bypass graft surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Visceral and subcutaneous adipose tissue thickness in patients who develop postoperative atrial fibrillation after coronary artery bypass graft surgery.
Other: Postoperative AF Group
Visceral and subcutaneous adipose tissue thickness in patients who do not develop postoperative atrial fibrillation after coronary artery bypass graft surgery.
Other: Non-AF Group
In patients undergoing coronary artery bypass graft surgery, ultrasound-guided measurements of visceral and subcutaneous adipose tissue will be performed preoperatively. The relationship between adipose tissue thickness and the development of postoperative atrial fibrillation will be evaluated by comparing patients who develop AF with those who do not.
In patients undergoing coronary artery bypass graft surgery, ultrasound-guided measurements of visceral and subcutaneous adipose tissue will be performed preoperatively. The relationship between adipose tissue thickness and the development of postoperative atrial fibrillation will be evaluated by comparing patients who develop AF with those who do not.
Effect of visceral adipose tissue thickness on postoperative atrial fibrillation
Preoperative ultrasound-guided measurement of visceral adipose tissue thickness will be performed. The association between visceral fat thickness and the development of postoperative atrial fibrillation will be evaluated.
Time frame: Within 7 days after coronary artery bypass graft surgery or until hospital discharge
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 8 months is below that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital